Market Overview

UPDATE: BMO Capital Markets Reiterates Market Perform Rating, Lowers PT on C.R. Bard

Related BCR
Earnings Scheduled For October 22, 2014
The Lutonix® 035 Drug Coated Balloon Is The First And Only FDA-Approved DCB Available In The U.S. For The Treatment Of Femoropopliteal Occlusive Disease

In a report published Friday, BMO Capital Markets reiterated its Market Perform rating on C.R. Bard (NYSE: BCR), but lowered its price target from $102.00 to $99.00.

BMO Capital Markets noted, “Management is embarking on an impressive strategic plan, which should bear fruit over time. Near term, we believe the 2013 EPS guidance will disappoint, the level of investment ramp will seem daunting, and investment ahead of an actual win will be questioned. Should this be pulled off, BCR may once again be a high-quality revenue and EPS growth company, and we commend management in taking the difficult first step.”

C.R. Bard closed on Thursday at $102.07.

Latest Ratings for BCR

DateFirmActionFromTo
Jul 2014CitigroupMaintainsNeutral
Jul 2014JefferiesMaintainsHold
Jul 2014JP MorganMaintainsNeutral

View More Analyst Ratings for BCR
View the Latest Analyst Ratings

Posted-In: BMO Capital MarketsAnalyst Color Price Target Analyst Ratings

 

Related Articles (BCR)

Around the Web, We're Loving...

Get Benzinga's Newsletters